Background: Global prescription drug use has been increasing continuously for decades.
| INTRODUCTION
In the United States, global prescription drug use has been increasing continuously for decades and are responsible for a rise in drugrelated spending and an increase in medication-related adverse outcomes. 1 Reports show that 46.9% of the population had taken at least one prescription drug in a 30-day window in 2011-2014, compared to 39 .1% between 1988 and 1994, and that 10.9% of the population has had five or more prescription drugs in a 30-day window in 2011-2014, compared to 4.0% in 1988-1994. 1 Similar findings are reported among European Union member states in the 2014 European health interview survey, with 48% of population having used prescription medications during a 2-week period. 2 Based on the 2013 national ambulatory medical care survey, the most frequently prescribed non-antibiotic therapeutic classes were analgesics (including nonsteroidal anti-inflammatory drugs, NSAIDs), antihyperlipidemic agents, antidepressants and antidiabetic agents. 3 The gut microbiome, a key contributor to human health with numerous associations to human diseases including nongastrointestinal conditions, 4 can be altered severely by prescription drug use. Antibiotics have a well-described impact on the intestinal microbiome with long-standing effects in patients, 5, 6 and it is known that chemotherapy induces specific gut microbiome dysbiosis. 7, 8 Maurice et al evaluated the impact of a variety of drugs, including antibiotics, digoxin, phenacetin and sulfasalazine, and found that antibiotics had the greatest impact on the gut microbiome. 9 Recently, Falony et al showed that medication has the strongest combined effect size on the microbiome. 10 In the present work, we systematically review studies reporting non-antibiotic prescription drug-induced human gut microbiome changes, focusing on the most frequently prescribed therapeutic drug categories from the aforementioned national ambulatory medical care survey. 1 
| MATERIALS AND METHODS

| Search strategy for the systematic review
We conducted a systematic review of studies that evaluated association between medications and members of the intestinal microbiome. We followed the recommended "Preferred Reporting
Items for Systematic Reviews and Meta-analyses" (PRISMA) guidelines 11 for our selections. Moreover, our methods are consistent with those of previously published systematic reviews in the field.
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| Inclusion and exclusion criteria
All observational, prospective or retrospective, cross-sectional, casecontrol, cohort studies or intervention studies were included in the search strategy if they evaluated prescription drug-induced gut microbiome changes in humans and were based on culture-independent molecular techniques. We did not include studies reporting effects of antibiotics on the gut microbiome as these have been well-studied and are outside the scope of our review. We investigated studies that reported intestinal microbiota changes associated with proton pump inhibitors (PPIs), metformin, NSAIDs, opioids, statins and antipsychotics. We searched for eligible studies in PubMed, EBSCO, Web of Science, SPORTSdiscus, Scopus, EMBASE and Ovid
Medline for indexed articles and abstracts published in English until
September 2017, as detailed in Data S1. We excluded studies that included preclinical models and those that focused on the gastric microbiota or were based on culture-dependent techniques.
| Analysis of the search results
All titles and abstracts found by the search strategy as reported in Data S1 were screened for relevance by EM. Titles and abstracts were then retrieved in full and evaluated for inclusion eligibility in the systematic review by EM and QLB, independently. Eligibility results were compared and discussed between EM and QLB to finally retain 20 studies for report in the systematic review, as detailed in Figure 1 .
| Definition of terms used to describe the microbiome
Alpha (a) diversity is defined as the microbiota diversity within an individual site or sample diversity, and gives one value per sample. 15 Several metrics can be used to described a diversity: Shannon index, Chao1 index, operational taxonomic unit (OTU) or species count or phylogenetic diversity. Beta (b) diversity represents the intervariability or diversity between separate samples. 15 b diversity describes how samples cluster together. Relative abundance is the per cent composition of a specific taxon or a specific specie, relative to the total number of taxa or species in the gut microbiome. An OTU is a population of phylogenetically related organisms, grouped on the basis of DNA sequence similarity. Usually, a 97% similarity level is used to group similar sequences into an OTU. 15 3 | RESULTS
| Proton pump inhibitors
Proton pump inhibitors are often prescribed for prevention and treatment of gastroesophageal reflux and peptic ulcer disease 16, 17 and rank eighth among the top therapeutic prescription classes in the United States. 18 The relative efficacy and safety of PPIs have contributed to their significant overutilisation. 19, 20 However, metaanalyses have shown that PPI use was associated with increased incidence of Clostridium difficile infection, 21, 22 higher rates of C.
difficile recurrence in hospitalised patients, 23 increased risk of other enteric infections 24, 25 and community-acquired Streptococcus pneumoniae. 26 A recent study including 400 cirrhotic patients reported that PPI prescription was an independent predictor of infection.
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LE BASTARD ET AL. University Medical Center, the Netherlands. No significant change in a diversity was found in any of the three cohorts when considered separately. However, in a combined analysis of all three data sets, they identified a significant decrease in a diversity of PPI users compared to non-users with Shannon (P = .01) and species richness (P = .02) metrics. 30 Moreover, Zhernakova et al in another cohort of 1135 Dutch participants, found that PPI medication was strongly associated with composition distance (adonis R 2 = .004, adjusted P = .0006), a measure of b diversity that here shows PPI use to be associated with specific changes in the architecture of the intestinal microbiome. 29 The same significant change in the overall gut microbiota architecture after PPI use was previously reported by Bajaj et al in controls and in patients with cirrhosis (P < .0001). 31 A study by Seto et al also found a decrease in a diversity after both 1 week and 1 month of PPI treatment (observed OTUs, P = .004), in line with the trend found in treatment-na€ ıve patients infected with C. difficile. 32 In a trial with 12 healthy volunteers, Freedberg et al found that a 4-week regimen of PPI medication (omeprazole 40 mg twice) was not associated with within-individual changes in diversity. 33 O'Donoghue et al found that PPI use was significantly associated with increased microbial diversity, but only in patients receiving more than two antibiotics (P < .01) and suggested that PPI use may counter antibiotics-associated dysbiosis. justed P-value association with PPI use <.05), as detailed in Table 1 .
The strongest association was with a Bifidobacterium OTU, followed by a Streptococcus OTU (adjusted P-value association with PPI use
<10 À4
). At the level of species, seven were found to be negatively associated with PPI use, mainly assigned to Erysipelotrichales or Clostridiales, and 24 were found positively associated with PPI use.
At the level of genera, nine were found to be negatively associated with PPI use, which were largely Firmicutes, with members of the Microbiome Project data to determine body site preferences of bacteria, they also found that microbial families more abundant in PPI users were more often found in the mouth/throat, skin/nose or vaginal sites than in the gut. Lactobacillus salivarius were increased in participants using PPI in each cohort. None of the individual cohorts contained any significantly decreased taxa (adjusted P <.05). In Cohort 1, 41 OTU were significantly increased, including the family Enterococcoceae, the genera Streptococcus, Veillonella and Enterococcus. In Cohort 2, PPI use was associated with an increase in 12 OTU, including the family Lactobacillaceae, the genera Streptococcus and Lactobacillus. In Cohort 3, 18 OTU were significantly increased, including the order Lactobacillales. Another important finding was the over-representation of multiple oral bacteria in the faecal microbiome of PPI-users, the most significantly increased being genera Rothia, Scardovia and Actinomyces (adjusted P <.05).
30
In a prospective cohort study of 98 hospitalised patients, Vincent et al found that PPI medication was positively associated with Potyvirus (P = .006), Morganella (P = .011) and Pyramidobacter (P = .04);
and negatively associated with Adlercreutzia (P = .003), Mitsuokella (P = .004), unclassified Clostridiaceae (P = .004), Campylobacter (P = .006), Pseudoflavonifractor (P = .007), Coprobacter (P = .01),
Ruminococcus (P = .03), unclassified Clostridiales Family XI (P = .03)
and Coprobacillus (P = .04). 36 
| Metformin
Metformin, a drug that lowers oral blood glucose, is one of the most widely prescribed medications for type 2 diabetes (T2D) patients. 37 However, about 30% of metformin-treated patients report adverse gastrointestinal effects, including abdominal pain and diarrhoea which may be linked to metformin-induced dysbiosis. (n = 14), T2D patients not treated with metformin (n = 14) and control participants (n = 84). They did not observe differences between T2D patients treated with metformin and those not treated with metformin in terms of a diversity (P = .557). However, b diversity analysis revealed a significant difference between metformin-treated T2D patients and those not treated with metformin (P = .036). 40 Moreover, Zhernakova et al in a cohort of 1135 Dutch participants found that metformin medication was strongly associated with composition distance (adonis R 2 = .002, adjusted P = .034), a measure of b diversity demonstrating differences in the bacterial community structure associated with metformin use. 29 
| Taxonomic changes in the gut microbiota of metformin users
Forslund et al found that T2D metformin-treated patients exhibited a significant decrease in Intestinibacter and a significant increase in Escherichia, after correcting for gender (adjusted P = 1.80E-12 and 9.62E-13, respectively), body mass index (adjusted P = 4.10E-10 and 4.10E-10, respectively) and fasting levels of plasma glucose (adjusted P = 3.28E-08 and 2.32E-11, respectively) and serum insulin (adjusted P = 1.48E-10 and 4.66E-12, respectively). Another independent T2D cohort confirmed similarly decreased Intestinibacter (P = .032) and increased in Escherichia (P = .049) in T2D metformin-treated patients (n = 26) compared to T2D patients without metformin treatment (n = 8).
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In stool samples from 1179 LifeLines-DEEP participants from the Netherlands, 41 metformin was also positively associated with E. coli (adjusted P = .003), and negatively associated with Bacteroides dorei (adjusted P = .049), Coprococcus comes (adjusted P = .011), Dorea formicigenerans (adjusted P-value = .063), Dorea longicatena (adjusted P-value = .085), Clostridium bartlettii (adjusted P-value = .047), and unclassified Peptostreptococcaceae (adjusted P-value = .011). 29 Karlsson et al also reported, in a cohort of 145 European women, that T2D patients treated with metformin had increased relative abundances of 103 species, mainly members of family Enterobacteriaceae, including E. coli (adjusted P = .004), Shigella (adjusted P = .005), Klebsiella (adjusted P = .013), Citrobacter (adjusted P = .007), Enterobacter cloaceae (adjusted P = .013), and Salmonella enterica (adjusted P = .03), and decreased relative abundances of 18 species including C. bartlettii (adjusted P = .006), Mobiluncus mulieris
and Eubacterium siraeum (adjusted P .016). 42 Using linear discriminant analysis, de la Cuesta-Zuluaga et al showed that OTUs from Prevotella and Megasphaera were enriched in patients treated with metformin compared to patients not treated with metformin, whereas OTUs from Oscillospira, Barnesiellaceae and Clostridiaceae 02d06 were depleted in T2D patients treated with metformin compared to patients not treated with metformin. Moreover, when pooling mucin-degrading and butyrate-producing bacteria, they reported that Akkermansia muciniphila and Butyrivibrio were more abundant (3.4 times, adjusted P-value = .01; 4.4 times, adjusted P-value = .21, respectively) in T2D patients treated with metformin compared patients not treated with metformin. 40 Wu et al randomly assigned recently diagnosed, treatment-na€ ıve T2D patients to receive either metformin (n = 22) or placebo treatment (n = 18) for 4 months in a double-blind study. They found that administration of metformin for 2 and 4 months resulted in significant changes in the relative abundance of 81 and 86 bacterial strains, respectively, most of which belonged to Gammaproteobacteria and Firmicutes (adjusted P-value <.05). At the genera level, they reported an increase in Escherichia (log2 fold change: 2.638, adjusted P = .0002 at month 2; log2 fold change: 2.462, adjusted P = .0002 at month 4) and a decrease in Intestinibacter (log2 fold change:
À1.69, adjusted P = .0002 at month 2; log2 fold change: À2.12, adjusted P = 1.73E-07 at month 4) in the metformin-treated group.
Moreover, the taxonomic alterations reported after 2 and 4 months of metformin correlated with those observed in a subset of the placebo group switched to receive metformin (n = 13) 6 months after the start of the study, with increase in Escherichia (log2 fold change:
2.377, adjusted P = .048), Bifidobacterium (log2 fold change: 1.564, adjusted P = .038) and Intestinibacter (log2 fold change: À1.042, adjusted P = .072). They also reported an increase in relative abundance of A. muciniphila in participants treated with metformin for 4 months, but did not find significant correlations between HbA1c
and A. muciniphila (P > .1). 43 
| Nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs are widely prescribed for pain and inflammatory conditions. 44 NSAIDs block the biosynthesis of prostanoids via inhibition the cyclooxygenase-1 and -2 enzymes. 45 These medications are commonly associated with adverse gastrointestinal events. 
NSAID users
In a human cohort with 155 participants, Rogers et al found that the relative abundance of a specific OTU in family Enterobacteriaceae was significantly higher (P < .0001) in participants using the NSAID naproxen (20%) than in participants not using any medications (0.7%). Celecoxib and ibuprofen use were also associated with increased bacterial families Enterococcaceae, Enterobacteriaceae and Erysipelotrichaceae. Family Acidaminococcaceae was significantly more prevalent in NSAID users than in those not using any medication (P = .025). Bacteria from families Desulfovibrionaceae, Enterococcaceae and Erysipelotrichaceae were also more common in NSAID users than in controls. 47 For ketorolac, Alistipes was enriched compared to controls. Propionibacteriaceae, Pseudomonadaceae, Puniceicoccaceae and Rikenellaceae were more abundant in ibuprofen users than in controls or in naproxen users. They also showed that the area under the curve (AUC) for prediction of aspirin medica- 48 In a cohort of 98 hospitalised patients, using a multivariate analysis, use of NSAIDs was associated with a significant increase in unclassified Clostridiales Family XI (estimate = 3.76, P = .058) and a significant decrease in the relative abundance of Clostridium (estimate = À2.1, P = .020). 36 In contrast, a study from Bokulich et al showed that sort-term exposure to celecoxib did not induce significant taxonomic changes in faecal samples. 46 
| Opioids
Morphine is often the drug of choice in cases of moderate or severe pain. 49 However, previous works demonstrated that opioid drugs enable bacterial translocation by means of gut barrier disruption.
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3.4.1 | Richness and diversity in the gut microbiota of opioid users
In a cohort of 98 hospitalised patients, Vincent et al found that opioid treatment was associated with an increase in a diversity in a cohort of hospitalised patients (estimate = 0.13, P = .0202). 36 In a cohort of patients with hepatic encephalopathy (HE), ß diversity tests revealed a significant difference between HE patients on opioids compared to HE patients not on opioids (P = .05) as well as between patients without HE on opioids vs not on opioids (P = .03). 53 Moreover, Zhernakova et al in a cohort of 1135 Dutch participants, found that opioid medication was strongly associated with composition distance (adonis R 2 = .002, adjusted P = .01), a measure of ß diversity showing that opioid use is associated with specific changes in the architecture of the intestinal microbiome. In a cohort of 98 hospitalised patients, opioid use was positively associated with Parabacteroides (P = .003), Propionimicrobium (P = .004), Alistipes (P = .016), Sutterella (P = .017), Clostridium (P = .026), Bifidobacterium (P = .026), unclassified Lachnospiraceae (P = .0295) and Pyramidobacter (P = .038), and negatively associated with Polyomavirus (P = .0002), Pseudomonas (P = .0003), unclassified Ruminococcaceae (p = .003), Candida (P = .019) and Megamonas (P = .028). 36 Acharya et al reported that Clostridiales XIV (P = .04), Ruminococcaceae (P = .02) and Bacteroidaceae (P = .03) were decreased in morphine treated patients. Using linear discriminant analysis, HE patients on opioids had increased Bifidobacterium and decreased Roseburia, Lachnospiraceae, and unclassified Clostridiales family XIV compared to HE patients not on opioids. Moreover, non-HE patients on opioids had increased Peptostreptococcaceae and decreased Parasutterella compared to non-HE patients not on opioids. 53 Zhernakova et al showed that opioid medication was positively associated with Alistipes (coefficient = 0.069, FDR corrected P = .092) and negatively associated with Roseburia inulinivorans Alistipes (coefficient = À0.099, FDR corrected P = .058). with increased relative abundance of Burkholderiaceae (P = 4.79E-09), Propionibacteriaceae (P = .00025), Enterococcaceae (P = .0004), Actinomycetaceae (P = .003) and Enterobacteriaceae (P = .007) in statin users. None of these contributed to the differences observed between idiopathic Parkinson's disease patients and controls. 56 In the 1135-participant Dutch cohort, 29 statin use was positively associated with S. parasanguinis (coefficient = 0.056, adjusted P = .003),
Streptococcus vestibularis (coefficient = 0.037, adjusted P = .011),
Clostridium bolteae (coefficient = 0.025, adjusted P = .037),
Ruminococcus torques (coefficient = 0.044, adjusted P = .037),
Ruminococcus bacterium (coefficient = .023, adjusted P = .037) and
Coprobacillus (coefficient = 0.03, adjusted P = .048); and negatively associated with Eubacterium ramulus (coefficient = À0.052, adjusted LE BASTARD ET AL.
formicigenerans (coefficient = À0.041, adjusted P = .030), D. longicatena (coefficient = À0.090, adjusted P = .00006) and Ruminococcus lactaris (coefficient = À0.075, adjusted P = .073). 29 
| Antipsychotics
Second-generation antipsychotics are antipsychotics approved by the Federal Drug Administration for treating agitation associated with schizophrenia and bipolar disorders. 57 However, a frequent side effect associated with these medications that limits their use is weight gain and increased visceral fat, 58 suggesting a potential impact of these drugs on the gut microbiome. Clayton distance metric, AMOVA, P = .04), and remained significant after adjusting for age, body mass index and benzodiazepine treatment (P = .02). 59 In a paediatric cohort, long-term Risperidone treatment (>12 consecutive months) was associated with significantly higher a diversity (Shannon index, 5.9 vs 5.2, respectively, P < .05) when compared with antipsychotic-na€ ıve psychiatric controls. ß diversity was significantly different in the chronic Risperidone group when compared with antipsychotic-na€ ıve psychiatric controls (ANOSIM, R = .516, P < .05). This indicates that a robust difference exists between the overall intestinal microbial profiles of the two groups. 60 Moreover, in the 1135 participants from a Dutch cohort, tricyclic antidepressants (adonis R 2 = .002, adjusted P = .01) and selective serotonin reuptake inhibitors showed a similarly significant association with composition (adonis R 2 = .003, adjusted P = .02). Akkermansia (P = .0006) and Sutterella in atypical antipsychotic-treated patients using linear discriminant analysis. 59 In paediatric psychiatrically ill male participants, Bahr et al documented that a chronic treatment with Risperidone was associated with an increase in body mass index and a lower ratio of Bacteroidetes:Firmicutes as compared with antipsychotic-na€ ıve psychiatric controls (ratio = 0.15 vs 1.24, respectively; P < .05). A longitudinal analysis highlighted a progressive decrease in the Bacteroidetes:Firmicutes ratio during Risperidone treatment that also correlated with body mass index gain. 60 In the 1135 participants from a Dutch cohort, antidepressants were positively associated with B. dorei (coefficient = 0.131, adjusted P = .051) and Coprococcus eutactus (coefficient = 0.114, adjusted P = .041), and negatively associated with Eubacterium hallii (coefficient = À0.084, adjusted P = .055). 29 
| DISCUSSION
Global prescription drug use has been increasing continuously for decades in the United States and in European countries. 1,2 The gut microbiome, mainly composed of bacteria which outnumber human cells, is a key contributor to human health. 61 Indeed, dysbiosis in the microbiome was identified and associated with predisposition to numerous human diseases. 4 Moreover, antibiotics have a welldescribed impact on the intestinal microbiome with long-standing effects in patients. 5, 6 Recently, Falony et al showed that medications were associated with microbiota compositional variation and explained the largest total variance of beta diversity. 10 Another population-based cohort showed a strong relationship between the gut microbiome and 19 drug groups, mainly PPI, statins and antibiotics. 29 Here, we systematically reviewed studies that reported prescription drug-induced gut microbiome alterations in humans, focusing on the most frequently prescribed drugs as documented by the 2013 national ambulatory medical care survey. 3 As such, we included studies that reported gut microbiome alterations associated with use of PPIs, metformin, NSAIDs, opioids, statins and antipsychotics.
| Summary of findings
We found that these prescription drugs have a notable impact on the intestinal microbiome, as summarised in Table 1 and Data S2-S7.
| Impact on richness and diversity in the gut microbiome
Regarding PPI use, the reports we reviewed here are somewhat contradictory in describing PPI effects on a diversity. However, the two largest observational cohort studies with the highest methodological quality, in addition to an intervention study on healthy volunteers, found that PPI use does significantly lower a diversity of the gut microbiota. 28, 30, 33 As for metformin and NSAIDs, the reviewed studies consistently reported that these drugs did not produce a significant change in a diversity. 29, 36, 39, 40, 46 For opioids, only one study evaluated a diversity and reported an increase in this metric in opioid users. 36 Atypical antipsychotic treatment was associated with decreased a diversity in one study 59 ; however, long-term Risperidone use (>12 months) was associated with increased a diversity in a small cohort of 28 children. 60 Reduced microbiome a diversity has well-documented associations with inflammatory states and diseases. 62, 63 Thus, a marked drop in a diversity was reported in "immune related" diseases like allergy, inflammatory bowel diseases, type 1 diabetes mellitus and multiple sclerosis, as well as colorectal cancer and metabolic disorders like obesity and T2D mellitus which primarily affect Western countries. 64, 65 Moreover, reduced a diversity was previously associated with increased susceptibility to C. difficile infection. 30, 66, 67 Since b diversity was altered for all drug classes but NSAIDs, this indicates that all of the remaining drugs reviewed produce compositional microbiome signatures capable of distinguishing users of these drugs from non-users. Since b diversity is a distance-based composite of all taxonomic differences, it makes sense that these changes would be accompanied by specific changes to the various underlying taxa.
| Taxonomic changes induced by medications
Two large observational studies and an intervention trial reported similar taxonomic changes in PPI users, with a signature decrease in
Clotridiales and increase in Actinomycetales, Micrococcaceae and Streptococcaceae. 28, 30, 33 Several studies also reported that PPI, metformin, NSAIDs, opioids and antipsychotics were associated with consistent increases in members of class Gammaproteobacteria, including Enterobacter, Escherichia, Klebsiella, Citrobacter, Salmonella and Proteus. These findings are strongest for PPI and metformin, as we found consistent results from several large observational or interventional studies. 28, 30, 33, 39, 42, 43 Thus, specific taxonomic alterations are consistently associated with some medications, essentially defining non-antibiotic prescription drug-induced bacterial profiles. These genera include the most frequently isolated pathogens from blood culture samples of patients with sepsis, especially critically ill and cancer patients. [68] [69] [70] In mice, domination by the family Enterobacteriaceae following antibiotic treatment resulted in clinically ill animals. 71 Mouse models also found that NSAIDs induced significant increases in members of families Enterobacteriaceae and Enterococcaceae. [72] [73] [74] [75] Lipopolysaccharides from Enterobacteriaceae have been shown to exacerbate NSAID-induced intestinal injury and increase intestinal permeability. 76, 77 Moreover, Enterobacteriaceae blooms are common in diseases involving inflammation, such as inflammatory bowel diseases, obesity, colorectal cancer and coeliac disease. 78 Taur et al reported that the domination of intestinal microbiota by commonly encountered organisms such as Enterococcus, Streptococcus, and various Proteobacteria was associated with subsequent bacteremia by the corresponding organism. 79 Enrichment in Enterococcus or Enterobacteriaceae also increase susceptibility to C. difficile infection. 67, 80 On the basis of these findings, we can hypothesise that increased Enterobacteriaceae and Enterococcaceae loads induced by drugs such as PPIs and metformin can potentially enhance susceptibility to infections, including C. difficile infection. 81, 82 Another potential link to clinical outcomes can be found in the taxonomic changes reported in patients who receive antipsychotic treatments. Bahr et al reported that long-term treatment with Risperidone is associated with an increase in body mass index and a decreased ratio of Bacteroidetes:Firmicutes. 60 This findings are in line with mouse experiments which reported that olanzapine and Risperidone induced increased relative abundance of Firmicutes and reduction in Bacteroidetes, a trend associated with weight gain [83] [84] [85] [86] and also found in obese mice compared to lean mice. 87 Thus, we speculate that taxonomic alterations induced by antipsychotic treatments may provide insight into why these medications are associated with weight gain. 
|
| Metformin
We reported here that metformin was associated with increases in the mucolytic bacterium Bifidobacterium bifidum, the mucin degrader A. muciniphila and several bacterial taxa producing short chain fatty acids, including Butyrivibrio, Megasphaera and Prevotella. 40 Moreover, short chain fatty acid concentrations (especially proprionate) were significantly higher in metformin users compared to non-users. 29 These findings corroborate previous results from mice models suggesting that the beneficial effects of metformin may be linked to an enhancement of the intestinal mucosal barrier. [105] [106] [107] In illustration, mice supplemented with A. muciniphila exhibited significant improvement in mucin-producing goblet cells, glucose tolerance and adipose tissue inflammation by inducing Foxp3 + regulatory T cells in the visceral adipose tissue. 106 Moreover, significant correlation between serum cholic acid, the most abundant primary biliary acid, and taxonomic composition observed by Napolitano et al in metformin-treated patients, suggests a role played by the biliary acid pool in the composition of the gut microbiome. 108 An interplay between the size and composition of the bile acid pool and the gut microbiota was previously reported. 109 The mechanism involved in metformininduced changes in gut microbiota could be an inhibition of the reab- 
| Antipsychotics
Elevation of interleukin 8 and interleukin 1ß was observed in mice treated with olanzapine. These inflammatory cytokines are known to be associated with obesity and implicated in insulin resistance. 119, 120 Moreover, leptin and ghrelin ratios could be impacted by these treatments, which is interesting as these markers are also directly implicated in the immune relationship between host and microbiota. In addition, direct anti-bacterial activity of olanzapine in the gut lumen is suspected. 83 This interplay may be selecting for or against certain members of the microbiome, leading to the signature taxonomic shifts mentioned earlier. In addition, intervention studies based on the principles of good clinical practice are warranted to better understand the impact of a medication on the human intestinal microbiome. In such randomised trials, it is necessary to take into account the effects of major confounding factors known to influence the gut microbiome, as reported by two large observational studies. 10, 29 One such double-blind and randomised trial was already performed to evaluate the effect of metformin in T2D patients. 43 Clinical trials are also needed to investigate the impact of drugs on the microbiota of other body sites, including cutaneous and lung microbiota.
| Modulation of the intestinal microbiome
As there is a clear association between the composition of the microbiome and prescription drug use, and evidence that altered gut microbiota may mediate some drug effects, another future direction may be to investigate these and other drugs with the goal of ameliorating or reversing some of their adverse effects. 43 Future studies should investigate modulation of the gut microbiota with live biotherapeutics based on microbiome biomarkers of drug-induced dysbiosis, to counter taxonomic changes associated with drug prescription that may predispose patients to adverse outcomes.
| CONCLUSIONS
In this work, we reviewed data from observational or intervention studies that reported medications induced gut microbiome alterations. We found that PPIs, metformin, NSAIDs, opioids, statins 
